Specific bone region localization of osteolytic versus osteoblastic lesions in a patient-derived xenograft model of bone metastatic prostate cancer
Objective: Bone metastasis occurs in up to 90% of men with advanced prostate cancer and leads to fractures, severe pain and therapy-resistance. Bone metastases induce a spectrum of types of bone lesions which can respond differently to therapy even within individual prostate cancer patients. Thus, t...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2016-10-01
|
| Series: | Asian Journal of Urology |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2214388216300613 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850229718430777344 |
|---|---|
| author | Takeshi Hirata Seung Chol Park Michelle T. Muldong Christina N. Wu Tomonori Yamaguchi Amy Strasner Omer Raheem Hiromi Kumon Robert L. Sah Nicholas A. Cacalano Catriona H.M. Jamieson Christopher J. Kane Koichi Masuda Anna A. Kulidjian Christina A.M. Jamieson |
| author_facet | Takeshi Hirata Seung Chol Park Michelle T. Muldong Christina N. Wu Tomonori Yamaguchi Amy Strasner Omer Raheem Hiromi Kumon Robert L. Sah Nicholas A. Cacalano Catriona H.M. Jamieson Christopher J. Kane Koichi Masuda Anna A. Kulidjian Christina A.M. Jamieson |
| author_sort | Takeshi Hirata |
| collection | DOAJ |
| description | Objective: Bone metastasis occurs in up to 90% of men with advanced prostate cancer and leads to fractures, severe pain and therapy-resistance. Bone metastases induce a spectrum of types of bone lesions which can respond differently to therapy even within individual prostate cancer patients. Thus, the special environment of the bone makes the disease more complicated and incurable. A model in which bone lesions are reproducibly induced that mirrors the complexity seen in patients would be invaluable for pre-clinical testing of novel treatments. The microstructural changes in the femurs of mice implanted with PCSD1, a new patient-derived xenograft from a surgical prostate cancer bone metastasis specimen, were determined. Methods: Quantitative micro-computed tomography (micro-CT) and histological analyses were performed to evaluate the effects of direct injection of PCSD1 cells or media alone (Control) into the right femurs of Rag2−/−γc−/− male mice. Results: Bone lesions formed only in femurs of mice injected with PCSD1 cells. Bone volume (BV) was significantly decreased at the proximal and distal ends of the femurs (p < 0.01) whereas BV (p < 0.05) and bone shaft diameter (p < 0.01) were significantly increased along the femur shaft. Conclusion: PCSD1 cells reproducibly induced bone loss leading to osteolytic lesions at the ends of the femur, and, in contrast, induced aberrant bone formation leading to osteoblastic lesions along the femur shaft. Therefore, the interaction of PCSD1 cells with different bone region-specific microenvironments specified the type of bone lesion. Our approach can be used to determine if different bone regions support more therapy resistant tumor growth, thus, requiring novel treatments. Keywords: Bone metastatic prostate cancer, Patient-derived xenograft, Bone microenvironment, Microstructural CT, Osteolytic lesions, Osteoblastic lesions |
| format | Article |
| id | doaj-art-d195ba8d9f63409e98fe8b47e7c19eb8 |
| institution | OA Journals |
| issn | 2214-3882 |
| language | English |
| publishDate | 2016-10-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Asian Journal of Urology |
| spelling | doaj-art-d195ba8d9f63409e98fe8b47e7c19eb82025-08-20T02:04:06ZengElsevierAsian Journal of Urology2214-38822016-10-013422923910.1016/j.ajur.2016.09.001Specific bone region localization of osteolytic versus osteoblastic lesions in a patient-derived xenograft model of bone metastatic prostate cancerTakeshi Hirata0Seung Chol Park1Michelle T. Muldong2Christina N. Wu3Tomonori Yamaguchi4Amy Strasner5Omer Raheem6Hiromi Kumon7Robert L. Sah8Nicholas A. Cacalano9Catriona H.M. Jamieson10Christopher J. Kane11Koichi Masuda12Anna A. Kulidjian13Christina A.M. Jamieson14Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, JapanDepartment of Urology, Wonkwang University School of Medicine and Hospital, Iksan, South KoreaMoores Cancer Center, University of California, San Diego, La Jolla, CA, USA; Department of Urology, University of California, San Diego, La Jolla, CA, USA; Department of Surgery, University of California, San Diego, La Jolla, CA, USAMoores Cancer Center, University of California, San Diego, La Jolla, CA, USA; Department of Medicine, University of California, San Diego, La Jolla, CA, USADepartment of Orthopaedic Surgery, School of Medicine, University of California, San Diego, La Jolla, CA, USAMoores Cancer Center, University of California, San Diego, La Jolla, CA, USA; Department of Urology, University of California, San Diego, La Jolla, CA, USA; Department of Surgery, University of California, San Diego, La Jolla, CA, USADepartment of Urology, University of California, San Diego, La Jolla, CA, USA; Department of Surgery, University of California, San Diego, La Jolla, CA, USADepartment of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, JapanDepartment of Bioengineering, University of California, San Diego, La Jolla, CA, USADepartment of Radiation Oncology, University of California at Los Angeles, Los Angeles, CA, USAMoores Cancer Center, University of California, San Diego, La Jolla, CA, USA; Department of Medicine, University of California, San Diego, La Jolla, CA, USAMoores Cancer Center, University of California, San Diego, La Jolla, CA, USA; Department of Urology, University of California, San Diego, La Jolla, CA, USA; Department of Surgery, University of California, San Diego, La Jolla, CA, USADepartment of Orthopaedic Surgery, School of Medicine, University of California, San Diego, La Jolla, CA, USAMoores Cancer Center, University of California, San Diego, La Jolla, CA, USA; Department of Orthopaedic Surgery, School of Medicine, University of California, San Diego, La Jolla, CA, USAMoores Cancer Center, University of California, San Diego, La Jolla, CA, USA; Department of Urology, University of California, San Diego, La Jolla, CA, USA; Department of Surgery, University of California, San Diego, La Jolla, CA, USA; Corresponding author. Department of Urology, Department of Surgery, Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.Objective: Bone metastasis occurs in up to 90% of men with advanced prostate cancer and leads to fractures, severe pain and therapy-resistance. Bone metastases induce a spectrum of types of bone lesions which can respond differently to therapy even within individual prostate cancer patients. Thus, the special environment of the bone makes the disease more complicated and incurable. A model in which bone lesions are reproducibly induced that mirrors the complexity seen in patients would be invaluable for pre-clinical testing of novel treatments. The microstructural changes in the femurs of mice implanted with PCSD1, a new patient-derived xenograft from a surgical prostate cancer bone metastasis specimen, were determined. Methods: Quantitative micro-computed tomography (micro-CT) and histological analyses were performed to evaluate the effects of direct injection of PCSD1 cells or media alone (Control) into the right femurs of Rag2−/−γc−/− male mice. Results: Bone lesions formed only in femurs of mice injected with PCSD1 cells. Bone volume (BV) was significantly decreased at the proximal and distal ends of the femurs (p < 0.01) whereas BV (p < 0.05) and bone shaft diameter (p < 0.01) were significantly increased along the femur shaft. Conclusion: PCSD1 cells reproducibly induced bone loss leading to osteolytic lesions at the ends of the femur, and, in contrast, induced aberrant bone formation leading to osteoblastic lesions along the femur shaft. Therefore, the interaction of PCSD1 cells with different bone region-specific microenvironments specified the type of bone lesion. Our approach can be used to determine if different bone regions support more therapy resistant tumor growth, thus, requiring novel treatments. Keywords: Bone metastatic prostate cancer, Patient-derived xenograft, Bone microenvironment, Microstructural CT, Osteolytic lesions, Osteoblastic lesionshttp://www.sciencedirect.com/science/article/pii/S2214388216300613 |
| spellingShingle | Takeshi Hirata Seung Chol Park Michelle T. Muldong Christina N. Wu Tomonori Yamaguchi Amy Strasner Omer Raheem Hiromi Kumon Robert L. Sah Nicholas A. Cacalano Catriona H.M. Jamieson Christopher J. Kane Koichi Masuda Anna A. Kulidjian Christina A.M. Jamieson Specific bone region localization of osteolytic versus osteoblastic lesions in a patient-derived xenograft model of bone metastatic prostate cancer Asian Journal of Urology |
| title | Specific bone region localization of osteolytic versus osteoblastic lesions in a patient-derived xenograft model of bone metastatic prostate cancer |
| title_full | Specific bone region localization of osteolytic versus osteoblastic lesions in a patient-derived xenograft model of bone metastatic prostate cancer |
| title_fullStr | Specific bone region localization of osteolytic versus osteoblastic lesions in a patient-derived xenograft model of bone metastatic prostate cancer |
| title_full_unstemmed | Specific bone region localization of osteolytic versus osteoblastic lesions in a patient-derived xenograft model of bone metastatic prostate cancer |
| title_short | Specific bone region localization of osteolytic versus osteoblastic lesions in a patient-derived xenograft model of bone metastatic prostate cancer |
| title_sort | specific bone region localization of osteolytic versus osteoblastic lesions in a patient derived xenograft model of bone metastatic prostate cancer |
| url | http://www.sciencedirect.com/science/article/pii/S2214388216300613 |
| work_keys_str_mv | AT takeshihirata specificboneregionlocalizationofosteolyticversusosteoblasticlesionsinapatientderivedxenograftmodelofbonemetastaticprostatecancer AT seungcholpark specificboneregionlocalizationofosteolyticversusosteoblasticlesionsinapatientderivedxenograftmodelofbonemetastaticprostatecancer AT michelletmuldong specificboneregionlocalizationofosteolyticversusosteoblasticlesionsinapatientderivedxenograftmodelofbonemetastaticprostatecancer AT christinanwu specificboneregionlocalizationofosteolyticversusosteoblasticlesionsinapatientderivedxenograftmodelofbonemetastaticprostatecancer AT tomonoriyamaguchi specificboneregionlocalizationofosteolyticversusosteoblasticlesionsinapatientderivedxenograftmodelofbonemetastaticprostatecancer AT amystrasner specificboneregionlocalizationofosteolyticversusosteoblasticlesionsinapatientderivedxenograftmodelofbonemetastaticprostatecancer AT omerraheem specificboneregionlocalizationofosteolyticversusosteoblasticlesionsinapatientderivedxenograftmodelofbonemetastaticprostatecancer AT hiromikumon specificboneregionlocalizationofosteolyticversusosteoblasticlesionsinapatientderivedxenograftmodelofbonemetastaticprostatecancer AT robertlsah specificboneregionlocalizationofosteolyticversusosteoblasticlesionsinapatientderivedxenograftmodelofbonemetastaticprostatecancer AT nicholasacacalano specificboneregionlocalizationofosteolyticversusosteoblasticlesionsinapatientderivedxenograftmodelofbonemetastaticprostatecancer AT catrionahmjamieson specificboneregionlocalizationofosteolyticversusosteoblasticlesionsinapatientderivedxenograftmodelofbonemetastaticprostatecancer AT christopherjkane specificboneregionlocalizationofosteolyticversusosteoblasticlesionsinapatientderivedxenograftmodelofbonemetastaticprostatecancer AT koichimasuda specificboneregionlocalizationofosteolyticversusosteoblasticlesionsinapatientderivedxenograftmodelofbonemetastaticprostatecancer AT annaakulidjian specificboneregionlocalizationofosteolyticversusosteoblasticlesionsinapatientderivedxenograftmodelofbonemetastaticprostatecancer AT christinaamjamieson specificboneregionlocalizationofosteolyticversusosteoblasticlesionsinapatientderivedxenograftmodelofbonemetastaticprostatecancer |